CROI 2015 Program and Abstracts

Oral Sessions

SessionW3Workshop

Room 6D

Workshop Conveners Jürgen K. Rockstroh , University of Bonn, Bonn, Germany David L. Thomas , The Johns Hopkins University, Baltimore, MD, US 14 Acute HCV: Is It Still Important to Diagnose and Treat? Arthur Y. Kim

2:30 pm– 4:30 pm Frontiers in Laboratory Science

Target audience: This session is directed to investigators and clinicians interested in learning about the main technological and conceptual developments in life sciences that are influencing HIV research or hold a significant potential for research. Level of knowledge: It is assumed that participants are familiar with the main technological and data analysis approaches used in HIV research. Objectives: At the completion of the session, participants will be able to: • Recognize the potential of and directions in the field of big data analysis. • Describe developments in immunophenotyping and in single-cell analyses. • Use the basic concepts of integration site analysis to understand current directions in HIV latency research. Workshop Conveners Amalio Telenti , The J. Craig Venter Institute, La Jolla, CA, US 10 Measuring Immunity 1 Cell at a Time Mario Roederer Vaccine Research Center, NIAID, NIH, Bethesda, MD, US 11 Studying Heterogeneity With Single Cell RNA-Sequencing Simon Quenneville Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland 12 Integration-Site Analysis Frederic D. Bushman University of Pennsylvania School of Medicine, Philadelphia, PA, US 13 Discovery and Modeling of Genomic Regulatory Networks With Big Data Hamid Bolouri Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US 2:30 pm– 4:30 pm Hepatitis C Care in the Interferon-Free Era Target audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection. Level of knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used. Objectives: At the completion of the session, participants will be able to: • Compare the various methods to stage liver disease. • Describe the differences and similarities in treatment of HIV/HCV-coinfected persons. • Recognize how treatment differs for persons with cirrhosis. SessionW4Workshop Room 613 Galit Alter , Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, US

1 Harvard Medical School, Boston, MA, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

Monday, February 23, 2015 • Oral Sessions

15 Chronic Genotype 1 Infection Debika Bhattacharya

University of California Los Angeles CARE Center, Los Angeles, CA, US

16 HCV Genotype 3: Our Next Challenge Arthur Y. Kim Massachusetts General Hospital, Boston, MA, US 17 HCV Cirrhotics With Early Decompensation Marion G. Peters University of California San Francisco, San Francisco, CA, US Opening Session 5:00 pm– 7:00 pm Welcome: Opening Session Opening Session Hosts Scott M. Hammer , Columbia University Medical Center/ New York-Presbyterian Hospital, New York, NY, US Julie M. Overbaugh , Fred Hutchinson Cancer Research Center, Seattle, WA, US Susan P. Buchbinder , San Francisco Department of Public Health, San Francisco, CA, US Session NL1 Lecture Bernard Fields Lecture 18 Hepatitis C: Light at the End of the Tunnel Charles M. Rice The Rockefeller University, New York, NY, US Session NL2 Lecture N’Galy-Mann Lecture 19 Antiretroviral Therapy: Past, Present, and Future David A. Cooper Kirby Institute, University of New South Wales, Sydney, Australia

4AB Auditorium

4AB Auditorium

4AB Auditorium

2

CROI 2015